Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RELIEF-SCC: IV Lidocaine for Sickle Cell Crisis
NCT04614610Phase 2Unknown
- Sponsor
- Community Medical Centers
- Start
- Jan 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in sickle cell disease (SCD) comparing Lidocaine with Placebo (2 arms). Primary endpoint: Change in pain at 30 minutes. Status: unknown.
02
Drugs
Lidocaine Hydrochloride Injection, without epinephrine
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT04614610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04614610.